CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 813 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
semaglutide 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01885208
NCT01885208Phase 3Completed
CompareCT.gov

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

Novo Nordisk A/S·interventional·Posted Jun 24, 2013·Updated Jun 13, 2019

In Brief

A Phase 3 clinical trial evaluating semaglutide and exenatide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 813 participants across 146 sites in 13 countries.

Detailed Summary

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Croatia, Finland, France, Germany, Greece, Italy, Netherlands, Puerto Rico, Serbia, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 24, 2013
Enrollment StartDec 2, 2013
Primary CompletionJul 13, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.0 years ago

Interventions

semaglutidedrug

One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly

exenatidedrug

One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly